首页 > 最新文献

European review for medical and pharmacological sciences最新文献

英文 中文
Ezetimibe reduces α-tocopherol levels in type 2 diabetes. 依折替米可降低2型糖尿病患者α-生育酚水平。
IF 3.3 4区 医学 Q1 Medicine Pub Date : 2025-07-01 DOI: 10.26355/eurrev_202507_37329
A Toffalini, N Vigolo, N Rolli, E Paviati, M Gelati, E Danese, G Zoppini

OBJECTIVE: α-tocopherol has a protective role against free radical-induced damage. The intestinal absorption of α-tocopherol is in part carried out by Nieman-Pick1-like1 protein, which is the target of ezetimibe, a drug used for the treatment of hypercholesterolemia. Ezetimibe is frequently prescribed to patients with type 2 diabetes in combination with statins. Therefore, the aim of the present study was to investigate the impact of ezetimibe treatment on the blood level of α-tocopherol. MATERIALS AND METHODS: Two hundred patients affected by type 2 diabetes, regularly attending the diabetes clinic, were recruited. All patients should not have received vitamin supplements in the six months preceding the study. α-tocopherol was measured by reverse-phase high-performance liquid chromatography with UV detection. Other laboratory parameters were determined by standard laboratory procedures. Patients were analyzed according to ezetimibe treatment. A linear multivariate regression analysis was used to estimate the factors associated with α-tocopherol level. RESULTS: The majority of patients were on ezetimibe/statin treatment. Patients taking ezetimibe showed a significantly lower α-tocopherol level, 29.9±5.7 vs. 32.9±7.0 μmol/L (p=0.006) compared to those not taking the drug. Ezetimibe was significantly and negatively associated with α-tocopherol level in the multivariate analysis (β standardized coefficient = -.217, p = .002). CONCLUSIONS: Treatment with ezetimibe can reduce α-tocopherol plasma levels by inhibiting the Niemann-Pick C1-like protein. Future studies are required to address the clinical implications of this finding.

Graphical abstract: https://www.europeanreview.org/wp/wp-content/uploads/Graphical-Abstract-NEW-2-scaled.jpg.

目的:α-生育酚具有抗自由基损伤的保护作用。α-生育酚的肠道吸收部分是由Nieman-Pick1-like1蛋白完成的,该蛋白是用于治疗高胆固醇血症的依zetimibe的靶标。依折替贝常与他汀类药物联合用于2型糖尿病患者。因此,本研究的目的是探讨依折麦比治疗对血液中α-生育酚水平的影响。材料与方法:招募了200名定期到糖尿病诊所就诊的2型糖尿病患者。所有患者在研究前6个月内都不应服用维生素补充剂。α-生育酚采用反相高效液相色谱-紫外检测法测定。其他实验室参数由标准实验室程序确定。根据依折麦布治疗方法对患者进行分析。采用多元线性回归分析α-生育酚水平的相关因素。结果:大多数患者接受依折替贝/他汀类药物治疗。服用依折替米比组α-生育酚水平(29.9±5.7 μmol/L vs. 32.9±7.0 μmol/L)明显低于未服用依折替米比组(p=0.006)。多因素分析显示依折替布与α-生育酚水平呈显著负相关(β标准化系数= -)。217, p = .002)。结论:依折替米贝可通过抑制Niemann-Pick c1样蛋白降低α-生育酚血浆水平。未来的研究需要解决这一发现的临床意义。图形摘要:https://www.europeanreview.org/wp/wp-content/uploads/Graphical-Abstract-NEW-2-scaled.jpg。
{"title":"Ezetimibe reduces α-tocopherol levels in type 2 diabetes.","authors":"A Toffalini, N Vigolo, N Rolli, E Paviati, M Gelati, E Danese, G Zoppini","doi":"10.26355/eurrev_202507_37329","DOIUrl":"https://doi.org/10.26355/eurrev_202507_37329","url":null,"abstract":"<p><p>OBJECTIVE: α-tocopherol has a protective role against free radical-induced damage. The intestinal absorption of α-tocopherol is in part carried out by Nieman-Pick1-like1 protein, which is the target of ezetimibe, a drug used for the treatment of hypercholesterolemia. Ezetimibe is frequently prescribed to patients with type 2 diabetes in combination with statins. Therefore, the aim of the present study was to investigate the impact of ezetimibe treatment on the blood level of α-tocopherol. MATERIALS AND METHODS: Two hundred patients affected by type 2 diabetes, regularly attending the diabetes clinic, were recruited. All patients should not have received vitamin supplements in the six months preceding the study. α-tocopherol was measured by reverse-phase high-performance liquid chromatography with UV detection. Other laboratory parameters were determined by standard laboratory procedures. Patients were analyzed according to ezetimibe treatment. A linear multivariate regression analysis was used to estimate the factors associated with α-tocopherol level. RESULTS: The majority of patients were on ezetimibe/statin treatment. Patients taking ezetimibe showed a significantly lower α-tocopherol level, 29.9±5.7 vs. 32.9±7.0 μmol/L (p=0.006) compared to those not taking the drug. Ezetimibe was significantly and negatively associated with α-tocopherol level in the multivariate analysis (β standardized coefficient = -.217, p = .002). CONCLUSIONS: Treatment with ezetimibe can reduce α-tocopherol plasma levels by inhibiting the Niemann-Pick C1-like protein. Future studies are required to address the clinical implications of this finding.</p><p><strong>Graphical abstract: </strong>https://www.europeanreview.org/wp/wp-content/uploads/Graphical-Abstract-NEW-2-scaled.jpg.</p>","PeriodicalId":12152,"journal":{"name":"European review for medical and pharmacological sciences","volume":"29 7","pages":"375-380"},"PeriodicalIF":3.3,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144759510","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Retraction Note: The efficacy and safety of a single dose of Polyhexamethylene Biguanide gynaecologic solution versus a seven-dose regimen of vaginal clindamycin cream in patients with bacterial vaginosis. 备注:单剂量聚六亚甲基双胍妇科溶液与七剂量阴道克林霉素乳膏在细菌性阴道病患者中的疗效和安全性。
IF 3.3 4区 医学 Q1 Medicine Pub Date : 2025-07-01 DOI: 10.26355/eurrev_202507_37337
M Minozzi, S Gerli, G C Di Renzo, E Papaleo, A Ferrari

The article "The efficacy and safety of a single dose of Polyhexamethylene Biguanide gynaecologic solution versus a seven-dose regimen of vaginal clindamycin cream in patients with bacterial vaginosis" by M. Minozzi, S. Gerli, G.C. Di Renzo, E. Papaleo, A. Ferrari, published in Eur Rev Med Pharmacol Sci 2008; 12 (1): 59-65-PMID: 18401974 has been retracted by the Authors in accordance with the Publisher and the Editor in Chief. Following some concerns raised by a third party regarding a possible high degree of textual similarity with a previously published paper, the journal has started an investigation. The authors were informed of the ongoing investigation and were asked to provide original data and clarify several other issues. In response, the authors requested the retraction of the manuscript, citing discrepancies related to the article and expressing a lack of confidence in the accuracy of the information submitted. This article has been retracted. The Publisher apologizes for any inconvenience this may cause. https://www.europeanreview.org/article/477.

M. Minozzi, S. Gerli, G.C. Di Renzo, E. Papaleo, a . Ferrari发表在2008年《Eur Rev Med Pharmacol Sci》上的文章“细菌性阴道病患者单剂量聚六亚甲基双胍妇科溶液与七剂量阴道格林霉素乳膏的疗效和安全性”;12 (1): 59-65-PMID: 18401974已根据出版商和主编的要求被作者撤回。由于第三方对该论文可能与先前发表的一篇论文高度相似提出了一些担忧,该期刊已开始调查。作者被告知正在进行的调查,并被要求提供原始数据和澄清其他几个问题。作为回应,作者要求撤回稿件,理由是与文章有关的差异,并表示对所提交信息的准确性缺乏信心。这篇文章已被撤回。对于由此造成的任何不便,出版商深表歉意。https://www.europeanreview.org/article/477。
{"title":"Retraction Note: The efficacy and safety of a single dose of Polyhexamethylene Biguanide gynaecologic solution versus a seven-dose regimen of vaginal clindamycin cream in patients with bacterial vaginosis.","authors":"M Minozzi, S Gerli, G C Di Renzo, E Papaleo, A Ferrari","doi":"10.26355/eurrev_202507_37337","DOIUrl":"https://doi.org/10.26355/eurrev_202507_37337","url":null,"abstract":"<p><p>The article \"The efficacy and safety of a single dose of Polyhexamethylene Biguanide gynaecologic solution versus a seven-dose regimen of vaginal clindamycin cream in patients with bacterial vaginosis\" by M. Minozzi, S. Gerli, G.C. Di Renzo, E. Papaleo, A. Ferrari, published in Eur Rev Med Pharmacol Sci 2008; 12 (1): 59-65-PMID: 18401974 has been retracted by the Authors in accordance with the Publisher and the Editor in Chief. Following some concerns raised by a third party regarding a possible high degree of textual similarity with a previously published paper, the journal has started an investigation. The authors were informed of the ongoing investigation and were asked to provide original data and clarify several other issues. In response, the authors requested the retraction of the manuscript, citing discrepancies related to the article and expressing a lack of confidence in the accuracy of the information submitted. This article has been retracted. The Publisher apologizes for any inconvenience this may cause. https://www.europeanreview.org/article/477.</p>","PeriodicalId":12152,"journal":{"name":"European review for medical and pharmacological sciences","volume":"29 7","pages":"347"},"PeriodicalIF":3.3,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144759511","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Anterior knee laxity and ACL magnetic resonance signals in healthy and ACL-reconstructed knees following exercise. 运动后健康和ACL重建膝关节的前膝关节松弛和前交叉韧带磁共振信号。
IF 3.3 4区 医学 Q1 Medicine Pub Date : 2025-07-01 DOI: 10.26355/eurrev_202507_37327
L Moretti, M Coviello, G Maccagnano, G D Cassano, A Carlet, E Favilla, B Moretti, G Solarino

Objective: The study compared anterior knee laxity and anterior cruciate ligament magnetic resonance signals between healthy and anterior cruciate ligament reconstruction (ACLR) knees after exercise to verify differences. This research can guide future training to reduce the risk of reinjury.

Materials and methods: Fifty-four male footballers between June and August 2022 were enrolled in this case-control study. Subjects who underwent ACLR in the previous 3 years (study group) were compared with healthy volunteers (control group). Each group consisted of twenty-seven patients. Data recorded were anterior tibial translation (ATT) expressed in millimeters using an arthrometer and the ratio of ACL to fat tissue signal intensity using magnetic resonance imaging. Measurements were collected at T0 (at rest), T1 (after 40 minutes of linear running of 3.5 miles), and T2 (after 90 minutes of a regular football match).

Results: No statistical difference was observed in demographic pre-analysis features. No difference was indicated between the two groups according to ATT. Conversely, ACL natives demonstrated significant increases in the ratio of ACL to fat tissue signal intensity when compared with ACLR in the three different measurements. Regarding differences within each group, we demonstrated that anterior knee laxity increased in both groups after 90 minutes of a regular football match. The ACL MRI signal did not differ in the study group, but it increased in the control group after exercise.

Conclusions: Although exhibiting distinct MRI signals, ACL-reconstructed tendons show similar post-exercise joint laxity as healthy ligaments. Looking ahead, leveraging specific insights could help tailor training sessions for preventive purposes.

目的:比较健康膝关节和前交叉韧带重建(ACLR)膝关节运动后的前膝关节松弛度和前交叉韧带磁共振信号,验证其差异。本研究可以指导今后的训练,降低再损伤的风险。材料和方法:在2022年6月至8月期间,54名男子足球运动员参加了这项病例对照研究。将3年内行ACLR的受试者(研究组)与健康志愿者(对照组)进行比较。每组27例。记录的数据是使用关节计以毫米表示的胫骨前平移(ATT)和使用磁共振成像的ACL与脂肪组织信号强度的比值。测量在T0(休息),T1(40分钟的3.5英里直线跑后)和T2(90分钟的常规足球比赛后)收集。结果:人口学预分析特征无统计学差异。根据ATT,两组之间没有差异。相反,在三种不同的测量中,与ACLR相比,ACL原生者的ACL与脂肪组织信号强度之比显着增加。关于每组之间的差异,我们证明了在90分钟的常规足球比赛后,两组的膝关节前侧松弛度都有所增加。前交叉韧带MRI信号在研究组中没有差异,但在运动后的对照组中有所增加。结论:尽管acl重建肌腱表现出不同的MRI信号,但其运动后关节松弛程度与健康韧带相似。展望未来,利用具体的见解可以帮助为预防目的量身定制培训课程。
{"title":"Anterior knee laxity and ACL magnetic resonance signals in healthy and ACL-reconstructed knees following exercise.","authors":"L Moretti, M Coviello, G Maccagnano, G D Cassano, A Carlet, E Favilla, B Moretti, G Solarino","doi":"10.26355/eurrev_202507_37327","DOIUrl":"https://doi.org/10.26355/eurrev_202507_37327","url":null,"abstract":"<p><strong>Objective: </strong>The study compared anterior knee laxity and anterior cruciate ligament magnetic resonance signals between healthy and anterior cruciate ligament reconstruction (ACLR) knees after exercise to verify differences. This research can guide future training to reduce the risk of reinjury.</p><p><strong>Materials and methods: </strong>Fifty-four male footballers between June and August 2022 were enrolled in this case-control study. Subjects who underwent ACLR in the previous 3 years (study group) were compared with healthy volunteers (control group). Each group consisted of twenty-seven patients. Data recorded were anterior tibial translation (ATT) expressed in millimeters using an arthrometer and the ratio of ACL to fat tissue signal intensity using magnetic resonance imaging. Measurements were collected at T0 (at rest), T1 (after 40 minutes of linear running of 3.5 miles), and T2 (after 90 minutes of a regular football match).</p><p><strong>Results: </strong>No statistical difference was observed in demographic pre-analysis features. No difference was indicated between the two groups according to ATT. Conversely, ACL natives demonstrated significant increases in the ratio of ACL to fat tissue signal intensity when compared with ACLR in the three different measurements. Regarding differences within each group, we demonstrated that anterior knee laxity increased in both groups after 90 minutes of a regular football match. The ACL MRI signal did not differ in the study group, but it increased in the control group after exercise.</p><p><strong>Conclusions: </strong>Although exhibiting distinct MRI signals, ACL-reconstructed tendons show similar post-exercise joint laxity as healthy ligaments. Looking ahead, leveraging specific insights could help tailor training sessions for preventive purposes.</p>","PeriodicalId":12152,"journal":{"name":"European review for medical and pharmacological sciences","volume":"29 7","pages":"349-355"},"PeriodicalIF":3.3,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144759508","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Expression of Concern. 表达关心。
IF 3.3 4区 医学 Q1 Medicine Pub Date : 2025-07-01 DOI: 10.26355/eurrev_202507_37339
N Authors Listed

The Editor in Chief and the Publisher are issuing an expression of concern regarding the following article: Unfer V, Carlomagno G, Rizzo P, Raffone E, Roseff S. Myo-inositol rather than D-chiro-inositol is able to improve oocyte quality in intracytoplasmic sperm injection cycles. A prospective, controlled, randomized trial. Eur Rev Med Pharmacol Sci. 2011 Apr; 15(4): 452-457. PMID: 21608442. This Expression of Concern is issued following a notification from a third party concerning a potential conflict of interest involving Dr. Unfer's role at Loli Pharma, the company marketing inositol-based products. This expression of concern aims to notify a possible bias arising from an undeclared conflict of interest. The authors have been notified of both the ongoing investigation and the publication of this notice. https://www.europeanreview.org/article/929.

主编和出版人发表了对以下文章的关注:Unfer V, caromagno G, Rizzo P, Raffone E, Roseff S.肌醇而不是d -手性肌醇能够改善胰岛素反应正常的多囊卵巢综合征患者的卵母细胞和胚胎质量。2011年4月;15(4): 452 - 457。PMID: 21608442。本关注表达是在第三方通知涉及Unfer博士在Loli Pharma(销售肌醇类产品的公司)的角色的潜在利益冲突后发布的。此表达关注的目的是通知由于未申报的利益冲突而可能产生的偏见。作者已被告知正在进行的调查和本通知的出版。https://www.europeanreview.org/article/929。
{"title":"Expression of Concern.","authors":"N Authors Listed","doi":"10.26355/eurrev_202507_37339","DOIUrl":"10.26355/eurrev_202507_37339","url":null,"abstract":"<p><p>The Editor in Chief and the Publisher are issuing an expression of concern regarding the following article: Unfer V, Carlomagno G, Rizzo P, Raffone E, Roseff S. Myo-inositol rather than D-chiro-inositol is able to improve oocyte quality in intracytoplasmic sperm injection cycles. A prospective, controlled, randomized trial. Eur Rev Med Pharmacol Sci. 2011 Apr; 15(4): 452-457. PMID: 21608442. This Expression of Concern is issued following a notification from a third party concerning a potential conflict of interest involving Dr. Unfer's role at Loli Pharma, the company marketing inositol-based products. This expression of concern aims to notify a possible bias arising from an undeclared conflict of interest. The authors have been notified of both the ongoing investigation and the publication of this notice. https://www.europeanreview.org/article/929.</p>","PeriodicalId":12152,"journal":{"name":"European review for medical and pharmacological sciences","volume":"29 7","pages":"348"},"PeriodicalIF":3.3,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144759509","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Decoding pharmacogenetics and metabolic panels in Jordanian women with polycystic ovary syndrome: a case-control study. 解码约旦多囊卵巢综合征妇女的药物遗传学和代谢组:一项病例对照研究。
IF 3.3 4区 医学 Q1 Medicine Pub Date : 2025-06-01 DOI: 10.26355/eurrev_202506_37276
A Yehya, A M Rababa'h, J Hamadneh, C L Shaffer

OBJECTIVE: This study aimed to assess the metabolic profiles and the frequency of the Serine/threonine kinase 11 (STK11) rs8111699 single-nucleotide polymorphism (SNP) among Jordanian women with polycystic ovary syndrome (PCOS). MATERIALS AND METHODS Ninety Jordanian women with PCOS and ninety healthy controls participated in the study. Metabolic characteristics were recorded, and direct sequencing was used to identify STK11 SNP genotypes. RESULTS: Among the PCOS patients, 23 (31.1%) had the wild-type (CC) genotype, while 39 (46.6%) and 28 (35.5%) had heterozygous (CG) and homozygous (GG) genotypes, respectively. There was no statistically significant difference in the genotype and allele distribution between the cases and controls (p=0.264 and p<0.702, respectively). Women carrying the minor G allele had poor metabolic profiles and more severe clinical features. CONCLUSIONS: The findings support the importance of early detection of PCOS, especially in high-risk populations, to enable timely preventive interventions. The interplay between genetic and metabolic profiles offers guidance for improving treatment outcomes in women with PCOS.

Graphical abstract: https://www.europeanreview.org/wp/wp-content/uploads/Graphical-abstract-14056.jpg.

目的:本研究旨在评估约旦多囊卵巢综合征(PCOS)女性丝氨酸/苏氨酸激酶11 (STK11) rs8111699单核苷酸多态性(SNP)的代谢谱和频率。材料与方法90名约旦多囊卵巢综合征妇女和90名健康对照者参加了这项研究。记录代谢特征,直接测序鉴定STK11 SNP基因型。结果:PCOS患者中,野生型(CC) 23例(31.1%),杂合型(CG) 39例(46.6%),纯合型(GG) 28例(35.5%)。两组间基因型及等位基因分布差异无统计学意义(p=0.264, p= p)。
{"title":"Decoding pharmacogenetics and metabolic panels in Jordanian women with polycystic ovary syndrome: a case-control study.","authors":"A Yehya, A M Rababa'h, J Hamadneh, C L Shaffer","doi":"10.26355/eurrev_202506_37276","DOIUrl":"https://doi.org/10.26355/eurrev_202506_37276","url":null,"abstract":"<p><p>OBJECTIVE: This study aimed to assess the metabolic profiles and the frequency of the Serine/threonine kinase 11 (STK11) rs8111699 single-nucleotide polymorphism (SNP) among Jordanian women with polycystic ovary syndrome (PCOS). MATERIALS AND METHODS Ninety Jordanian women with PCOS and ninety healthy controls participated in the study. Metabolic characteristics were recorded, and direct sequencing was used to identify STK11 SNP genotypes. RESULTS: Among the PCOS patients, 23 (31.1%) had the wild-type (CC) genotype, while 39 (46.6%) and 28 (35.5%) had heterozygous (CG) and homozygous (GG) genotypes, respectively. There was no statistically significant difference in the genotype and allele distribution between the cases and controls (p=0.264 and p<0.702, respectively). Women carrying the minor G allele had poor metabolic profiles and more severe clinical features. CONCLUSIONS: The findings support the importance of early detection of PCOS, especially in high-risk populations, to enable timely preventive interventions. The interplay between genetic and metabolic profiles offers guidance for improving treatment outcomes in women with PCOS.</p><p><strong>Graphical abstract: </strong>https://www.europeanreview.org/wp/wp-content/uploads/Graphical-abstract-14056.jpg.</p>","PeriodicalId":12152,"journal":{"name":"European review for medical and pharmacological sciences","volume":"29 6","pages":"339-346"},"PeriodicalIF":3.3,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144559620","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Retrospective comparison of functional outcomes in open partial laryngectomy vs. total laryngectomyfor locally advanced (T3, T4) laryngeal cancer. 开放性喉部分切除术与全喉切除术治疗局部晚期(T3, T4)喉癌功能结局的回顾性比较
IF 3.3 4区 医学 Q1 Medicine Pub Date : 2025-06-01 DOI: 10.26355/eurrev_202506_37271
J Pies, S Hackenberg, M Scheich, T Meyer, A Scherzad, M Goncalves

OBJECTIVE: Open partial laryngectomy (pLE), in cases not suited for transoral resection, aims to provide an oncologically safe resection, maintaining laryngeal function without the need for permanent tracheostomy. In cases requiring extensive resection, debate remains about whether pLE is feasible with a functional outcome or if total laryngectomy (tLE) is preferable. MATERIALS AND METHODS: This monocentric retrospective cohort study evaluated the resection of locally advanced (T3, T4) laryngeal carcinoma (LC) performed via open pLE or tLE between November 2010 and August 2023. Transoral resections, T1 and T2 cases were excluded. The presence of tracheostomy, the rate of oral feeding, the ability to phonate, and the oncologic outcome were assessed. RESULTS: The outcome of 38 pLEs and 56 tLEs was assessed. Adjuvant therapy was administered in 76% (n=29/38) pLEs and 47% (n=26/56) tLEs. While the oncologic results remained comparable between the two procedures (negative margins: p = 0.349; 5-year overall survival: p = 0.421), total laryngectomy (tLE) achieved better functional outcomes. Swallowing ability was markedly better after tLE (pLE vs. tLE: 39.5% vs. 91%, p < 0.001), particularly in patients with T4 tumors (pLE vs. tLE: 14% vs. 89%, p < 0.001) and in those over 65 years (pLE vs. tLE: 14% vs. 100%; p < 0.001). Overall, aspiration was the most frequent post-therapeutic complication after pLE, preventing unassisted oral intake in 58% of cases (22/38). The tracheostomy could be closed in 26% (n=10/38) of pLE-patients, at a median of 6.57 months (range 0.6-24 months). Consequently, after pLE 74% (n=28/38) of patients retained their tracheostomy at a median follow-up of 4 years. CONCLUSIONS: The low rates of tracheostoma closure, low rates of oral feeding over a median of 4 years, and R0 resection status of T4 tumors after pLE compared to tLE suggest patients with locally advanced LC are better suited for tLE.

Graphical abstract: https://www.europeanreview.org/wp/wp-content/uploads/Graphical-Abstract-NEW-1.jpg.

目的:在不适合经口切除的病例中,开放性喉部分切除术(pLE)旨在提供肿瘤安全的切除,在不需要永久性气管切开术的情况下维持喉功能。在需要广泛切除的病例中,争论仍然存在,即pLE是否具有功能性结果,或者是否更适合全喉切除术(tLE)。材料和方法:本单中心回顾性队列研究评估了2010年11月至2023年8月间通过开放pLE或tLE行局部晚期(T3, T4)喉癌(LC)切除术的患者。排除经口切除,T1和T2病例。评估了气管切开术、口服喂养率、发声能力和肿瘤预后。结果:对38例le和56例tLEs的预后进行了评估。76%的ple患者(n=29/38)和47%的tLEs患者(n=26/56)接受辅助治疗。两种手术的肿瘤结果具有可比性(阴性边缘:p = 0.349;5年总生存率:p = 0.421),全喉切除术(tLE)获得了更好的功能结局。术后吞咽能力明显改善(pLE vs tLE: 39.5% vs 91%, p < 0.001),特别是T4肿瘤患者(pLE vs tLE: 14% vs 89%, p < 0.001)和65岁以上患者(pLE vs tLE: 14% vs 100%;P < 0.001)。总体而言,误吸是pLE治疗后最常见的并发症,58%的病例(22/38)无法单独口服。26% (n=10/38)的ple患者气管切开术成功,中位时间为6.57个月(0.6-24个月)。因此,在pLE后,74% (n=28/38)的患者在中位随访4年期间保留了气管切开术。结论:与tLE相比,pLE术后气管吻合率低、中位4年口服喂养率低、T4肿瘤R0切除率低,提示局部晚期LC患者更适合tLE。图形摘要:https://www.europeanreview.org/wp/wp-content/uploads/Graphical-Abstract-NEW-1.jpg。
{"title":"Retrospective comparison of functional outcomes in open partial laryngectomy vs. total laryngectomyfor locally advanced (T3, T4) laryngeal cancer.","authors":"J Pies, S Hackenberg, M Scheich, T Meyer, A Scherzad, M Goncalves","doi":"10.26355/eurrev_202506_37271","DOIUrl":"https://doi.org/10.26355/eurrev_202506_37271","url":null,"abstract":"<p><p>OBJECTIVE: Open partial laryngectomy (pLE), in cases not suited for transoral resection, aims to provide an oncologically safe resection, maintaining laryngeal function without the need for permanent tracheostomy. In cases requiring extensive resection, debate remains about whether pLE is feasible with a functional outcome or if total laryngectomy (tLE) is preferable. MATERIALS AND METHODS: This monocentric retrospective cohort study evaluated the resection of locally advanced (T3, T4) laryngeal carcinoma (LC) performed via open pLE or tLE between November 2010 and August 2023. Transoral resections, T1 and T2 cases were excluded. The presence of tracheostomy, the rate of oral feeding, the ability to phonate, and the oncologic outcome were assessed. RESULTS: The outcome of 38 pLEs and 56 tLEs was assessed. Adjuvant therapy was administered in 76% (n=29/38) pLEs and 47% (n=26/56) tLEs. While the oncologic results remained comparable between the two procedures (negative margins: p = 0.349; 5-year overall survival: p = 0.421), total laryngectomy (tLE) achieved better functional outcomes. Swallowing ability was markedly better after tLE (pLE vs. tLE: 39.5% vs. 91%, p < 0.001), particularly in patients with T4 tumors (pLE vs. tLE: 14% vs. 89%, p < 0.001) and in those over 65 years (pLE vs. tLE: 14% vs. 100%; p < 0.001). Overall, aspiration was the most frequent post-therapeutic complication after pLE, preventing unassisted oral intake in 58% of cases (22/38). The tracheostomy could be closed in 26% (n=10/38) of pLE-patients, at a median of 6.57 months (range 0.6-24 months). Consequently, after pLE 74% (n=28/38) of patients retained their tracheostomy at a median follow-up of 4 years. CONCLUSIONS: The low rates of tracheostoma closure, low rates of oral feeding over a median of 4 years, and R0 resection status of T4 tumors after pLE compared to tLE suggest patients with locally advanced LC are better suited for tLE.</p><p><strong>Graphical abstract: </strong>https://www.europeanreview.org/wp/wp-content/uploads/Graphical-Abstract-NEW-1.jpg.</p>","PeriodicalId":12152,"journal":{"name":"European review for medical and pharmacological sciences","volume":"29 6","pages":"289-300"},"PeriodicalIF":3.3,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144559625","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Intra- and peri-meniscal polynucleotide injections for the treatment of symptomatic degenerative meniscus of the knee: 1-year findings from a prospective clinical trial. 半月板内和半月板周围注射多核苷酸治疗膝关节症状性退行性半月板:1年前瞻性临床试验结果
IF 3.3 4区 医学 Q1 Medicine Pub Date : 2025-06-01 DOI: 10.26355/eurrev_202506_37273
G Anzillotti, P Conte, E M Bertolino, A Ferrero, B Di Matteo, M Vacca, M Di Martino, D Altomare, N Magarelli, E Lanza, P Verdonk, E Kon

OBJECTIVE: Degenerative meniscal lesions consist of an alteration of the meniscal structure, eventually leading to pain and dysfunction. In the absence of mechanical symptoms, meniscectomy should be considered the last resort. Polynucleotides represent a novel treatment option which have shown promising results in different fields, including knee osteoarthritis. Hence, this study aimed to evaluate the safety and efficacy of a cycle of intra- and peri-meniscal polynucleotide injections for the treatment of degenerative meniscus. MATERIALS AND METHODS: This prospective study included 30 patients aged 25-65 with degenerative meniscal tears confirmed by MRI. Eligible patients were treated with three intra- and peri-meniscal injections of polynucleotides, administered with a two-week time interval under ultrasound guidance. The primary outcome was improvement in the overall Knee Injury and Osteoarthritis Outcome Score (KOOS) by at least 10 points from baseline to 12-month follow-up. Secondary outcomes included Visual Analog Scale (VAS) for pain, the International Knee Documentation Committee (IKDC) score, and the Tegner Activity Scale. Safety was assessed through the monitoring of adverse events. RESULTS: Twenty-four patients completed the 12-month follow-up. KOOS scores showed a statistically significant improvement from a mean of 61.99 at baseline to 84.32 at 12 months [95% CI: (79.25, 89.4); p<0.001]. VAS mm scores also decreased significantly, from 62.68 at baseline to 20.63 at 12 months [95% CI, (12.84, 28.41), p<0.001]. Improvements in IKDC and Tegner scores were observed but plateaued after 6 months. No adverse events were reported throughout the entire study period. CONCLUSIONS: A cycle of three intra- and peri-meniscal poly-nucleotides injections is able to provide statistically significant improvements in clinical scores up to 1 year of follow-up in patients affected by symptomatic degenerative meniscus of the knee.

Graphical abstract: https://www.europeanreview.org/wp/wp-content/uploads/Graphical-abstract-1-2.jpg.

目的:退行性半月板病变包括半月板结构的改变,最终导致疼痛和功能障碍。在没有机械症状的情况下,半月板切除术应被认为是最后的手段。多核苷酸代表了一种新的治疗选择,在不同的领域显示出有希望的结果,包括膝关节骨关节炎。因此,本研究旨在评估半月板内和半月板周围注射周期多核苷酸治疗退行性半月板的安全性和有效性。材料和方法:这项前瞻性研究包括30例年龄在25-65岁之间,经MRI证实患有退行性半月板撕裂的患者。符合条件的患者接受三次半月板内和半月板周围注射多核苷酸,在超声引导下间隔两周给药。主要结局是总体膝关节损伤和骨关节炎结局评分(oos)从基线到12个月随访至少改善10分。次要结果包括疼痛的视觉模拟量表(VAS)、国际膝关节文献委员会(IKDC)评分和Tegner活动量表。通过监测不良事件来评估安全性。结果:24例患者完成了12个月的随访。KOOS评分从基线时的平均61.99分改善到12个月时的平均84.32分[95% CI:(79.25, 89.4);图形摘要:https://www.europeanreview.org/wp/wp-content/uploads/Graphical-abstract-1-2.jpg。
{"title":"Intra- and peri-meniscal polynucleotide injections for the treatment of symptomatic degenerative meniscus of the knee: 1-year findings from a prospective clinical trial.","authors":"G Anzillotti, P Conte, E M Bertolino, A Ferrero, B Di Matteo, M Vacca, M Di Martino, D Altomare, N Magarelli, E Lanza, P Verdonk, E Kon","doi":"10.26355/eurrev_202506_37273","DOIUrl":"10.26355/eurrev_202506_37273","url":null,"abstract":"<p><p>OBJECTIVE: Degenerative meniscal lesions consist of an alteration of the meniscal structure, eventually leading to pain and dysfunction. In the absence of mechanical symptoms, meniscectomy should be considered the last resort. Polynucleotides represent a novel treatment option which have shown promising results in different fields, including knee osteoarthritis. Hence, this study aimed to evaluate the safety and efficacy of a cycle of intra- and peri-meniscal polynucleotide injections for the treatment of degenerative meniscus. MATERIALS AND METHODS: This prospective study included 30 patients aged 25-65 with degenerative meniscal tears confirmed by MRI. Eligible patients were treated with three intra- and peri-meniscal injections of polynucleotides, administered with a two-week time interval under ultrasound guidance. The primary outcome was improvement in the overall Knee Injury and Osteoarthritis Outcome Score (KOOS) by at least 10 points from baseline to 12-month follow-up. Secondary outcomes included Visual Analog Scale (VAS) for pain, the International Knee Documentation Committee (IKDC) score, and the Tegner Activity Scale. Safety was assessed through the monitoring of adverse events. RESULTS: Twenty-four patients completed the 12-month follow-up. KOOS scores showed a statistically significant improvement from a mean of 61.99 at baseline to 84.32 at 12 months [95% CI: (79.25, 89.4); p<0.001]. VAS mm scores also decreased significantly, from 62.68 at baseline to 20.63 at 12 months [95% CI, (12.84, 28.41), p<0.001]. Improvements in IKDC and Tegner scores were observed but plateaued after 6 months. No adverse events were reported throughout the entire study period. CONCLUSIONS: A cycle of three intra- and peri-meniscal poly-nucleotides injections is able to provide statistically significant improvements in clinical scores up to 1 year of follow-up in patients affected by symptomatic degenerative meniscus of the knee.</p><p><strong>Graphical abstract: </strong>https://www.europeanreview.org/wp/wp-content/uploads/Graphical-abstract-1-2.jpg.</p>","PeriodicalId":12152,"journal":{"name":"European review for medical and pharmacological sciences","volume":"29 6","pages":"313-323"},"PeriodicalIF":3.3,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144559623","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Expression of Concern. 表达关心。
IF 3.3 4区 医学 Q1 Medicine Pub Date : 2025-06-01 DOI: 10.26355/eurrev_202506_37270
N Authors Listed
<p><p>The Publisher, in agreement with the Editor-in-Chief, is issuing this Expression of Concern to inform readers that a formal investigation is currently underway regarding a set of published articles. Despite multiple attempts to contact the corresponding authors, we have not received any response to date. Further editorial actions, such as retraction or correction, will be taken as appropriate in due course. The articles under investigation fall into the following categories. These studies report extended follow-up periods, yet were published prior to the actual conclusion of the declared follow-up. This discrepancy raises serious concerns about the validity of the timeline and outcome reporting: Liao Y, Cheng S, Xiang J, Luo C. lncRNA CCHE1 increased proliferation, metastasis and invasion of non-small lung cancer cells and predicted poor survival in non-small lung cancer patients. Eur Rev Med Pharmacol Sci. 2018 Mar;22(6):1686-1692. doi: 10.26355/eurrev_201803_14581. PMID: 29630113. Yao N, Sun JQ, Yu L, Ma L, Guo BQ. LINC00968 accelerates the progression of epithelial ovarian cancer via mediating the cell cycle progression. Eur Rev Med Pharmacol Sci. 2019 Jun;23(11):4642-4649. doi: 10.26355/eurrev_201906_18043. PMID: 31210289. Hao XZ, Yang K. LncRNA MAGI2-AS3 suppresses the proliferation and invasion of non-small cell lung carcinoma through miRNA-23a-3p/PTEN axis. Eur Rev Med Pharmacol Sci. 2019 Sep;23(17):7399-7407. doi: 10.26355/eurrev_201909_18848. PMID: 31539127. Jiang J, Wu RH, Zhou HL, Li ZM, Kou D, Deng Z, Dong M, Chen LH. TGIF2 promotes cervical cancer metastasis by negatively regulating FCMR. Eur Rev Med Pharmacol Sci. 2020 Jun;24(11):5953-5962. doi: 10.26355/eurrev_202006_21488. PMID: 32572908. These articles have been questioned as they appear to reuse identical or similar graphical elements and images from a shared library across multiple unrelated studies: Xu CF, Liu P, Tan J, Hu DF. Long noncoding RNA LINC00052 suppressed the proliferation, migration and invasion of glioma cells by upregulating KLF6. Eur Rev Med Pharmacol Sci. 2019 Jun;23(11):4822-4827. doi: 10.26355/eurrev_201906_18068. PMID: 31210314. Zheng FX, Wang XQ, Zheng WX, Zhao J. Long noncoding RNA HOXA-AS2 promotes cell migration and invasion via upregulating IGF-2 in non-small cell lung cancer as an oncogene. Eur Rev Med Pharmacol Sci. 2019 Jun;23(11):4793-4799. doi: 10.26355/eurrev_201906_18064. PMID: 31210310.Liao J, Xie N. Long noncoding RNA DSCAM-AS1 functions as an oncogene in non-small cell lung cancer by targeting BCL11A. Eur Rev Med Pharmacol Sci. 2019 Feb;23(3):1087-1092. doi: 10.26355/eurrev_201902_16998. PMID: 30779076. Lu J, Xu FQ, Guo JJ, Lin PL, Meng Z, Hu LG, Li J, Li D, Lu XH, An Y. Long noncoding RNA GAS5 attenuates cardiac fibroblast proliferation in atrial fibrillation via repressing ALK5. Eur Rev Med Pharmacol Sci. 2019 Sep;23(17):7605-7610. doi: 10.26355/eurrev_201909_18883. PMID: 31539152. Shi JQ, Wang B, Cao XQ, Wang YX, Cheng
在主编的同意下,出版商发布此关注声明,通知读者,目前正在对一系列已发表的文章进行正式调查。尽管我们多次尝试联系通讯作者,但至今未收到任何回复。我们将在适当的时候采取进一步的编辑行动,如撤回或更正。被调查的物品可分为以下几类。这些研究报告了较长的随访期,但在宣布的随访实际结束之前发表。这一差异引起了人们对时间线和结果报告有效性的严重关注:廖莹,程生,向杰,罗超。lncRNA CCHE1增加非小细胞肺癌细胞的增殖、转移和侵袭,并预测非小细胞肺癌患者的生存率较差。中华医学杂志,2018;22(6):1686-1692。doi: 10.26355 / eurrev_201803_14581。PMID: 29630113。姚宁,孙建强,于磊,马磊,郭宝强。LINC00968通过介导细胞周期进程加速上皮性卵巢癌的进展。中华医学杂志,2019;23(11):4642-4649。doi: 10.26355 / eurrev_201906_18043。PMID: 31210289。郝晓贞,杨凯。LncRNA MAGI2-AS3通过miRNA-23a-3p/PTEN轴抑制非小细胞肺癌的增殖和侵袭。医药科学进展,2019;23(17):7399-7407。doi: 10.26355 / eurrev_201909_18848。PMID: 31539127。姜军,吴荣荣,周海龙,李志明,寇东,邓志,董明,陈丽玲。TGIF2通过负调控FCMR促进宫颈癌转移。中华医学杂志,2014;24(11):5953-5962。doi: 10.26355 / eurrev_202006_21488。PMID: 32572908。这些文章受到质疑,因为它们似乎在多个不相关的研究中重用了来自共享库的相同或相似的图形元素和图像:徐长鹏,刘鹏,谭杰,胡德芳。长链非编码RNA LINC00052通过上调KLF6抑制胶质瘤细胞的增殖、迁移和侵袭。中华医学杂志,2019;23(11):4822-4827。doi: 10.26355 / eurrev_201906_18068。PMID: 31210314。郑凤霞,王小强,郑文霞,赵军。龙非编码RNA HOXA-AS2作为癌基因通过上调IGF-2促进非小细胞肺癌细胞迁移和侵袭。中华医学杂志,2019;23(11):4793-4799。doi: 10.26355 / eurrev_201906_18064。PMID: 31210310。廖静,谢宁。长非编码RNA DSCAM-AS1靶向BCL11A在非小细胞肺癌中的作用。医药科学进展,2019;23(3):1087-1092。doi: 10.26355 / eurrev_201902_16998。PMID: 30779076。吕军,徐凤青,郭建军,林普乐,胡丽珍,李军,李东,卢晓华,安勇。长链非编码RNA GAS5通过抑制ALK5抑制心房颤动的心脏成纤维细胞增殖。医药科学进展,2019;23(17):7605-7610。doi: 10.26355 / eurrev_201909_18883。PMID: 31539152。石建强,王斌,曹小强,王云云,程霞,贾春林,温涛,罗炳军,刘志东。环状RNA_LARP4通过调节SMAD7的表达抑制非小细胞肺癌的进展。欧洲医学与药物科学,2020年2月;24(4):1863-1869。doi: 10.26355 / eurrev_202002_20364。PMID: 32141555。崔凯,张宏,王广光。MiR-483在乳腺癌中通过靶向SOX3抑制细胞增殖,促进细胞凋亡。医药科学进展,2019;23(5):2069-2074。doi: 10.26355 / eurrev_201903_17248。PMID: 30915751。任磊,翟辉,王晓林,李建中,夏玉华。Hsa_circ_0011946通过诱导EMT过程促进肝癌的迁移和侵袭。医药科学,2020;24(3):1108-1115。doi: 10.26355 / eurrev_202002_20161。PMID: 32096173。引用本文:陈瑞霞,刘海龙,杨丽丽,康红华,辛丽萍,黄立荣,郭启峰,王玉玲。环状RNA circRNA_0000285通过调控FUS促进宫颈癌的发展。医药科学进展,2019;23(20):8771-8778。doi: 10.26355 / eurrev_201910_19271。PMID: 31696463。刘涛,王伟,徐玉春,李志伟,周军。龙非编码RNA NEAT1靶向miR-29a-3p在人喉癌中的致癌作用。中华医学杂志,2019;23(14):6234-6241。doi: 10.26355 / eurrev_201907_18442。PMID: 31364125。长非编码RNA XIST通过海绵介导miR-200b-3p促进肝癌进展。医药科学进展,2019;23(22):9857-9862。doi: 10.26355 / eurrev_201911_19549。PMID: 31799653。翁晓东,严涛,刘春林。环状RNA_LARP4通过靶向FOXO3A抑制前列腺癌细胞迁移和侵袭。中华医学杂志,2020;24(10):5303-5309。doi: 10.26355 / eurrev_202005_21312。PMID: 32495863。何学勇,潘晓明,金敏,杨玉玲,杨志强,闫东,马建新。长链非编码RNA AK027294通过上调胃癌PCNA促进肿瘤生长。中华医学杂志,2019;23(13):5762-5769。doi: 10.26355 / eurrev_201907_18314。PMID: 31298327。王艳华,霍宝玲,李超,马刚,曹伟。 低敲长链非编码RNA SNHG7通过下调BDNF抑制甲状腺癌细胞增殖并促进细胞凋亡。中华医学杂志,2019;23(11):4815-4821。doi: 10.26355 / eurrev_201906_18067。PMID: 31210313。杨振涛,安芳,胡建东,赵文辉。长链非编码RNA AFAP1-AS1通过抑制RBM5的表达加速前列腺癌的增殖和转移。医药科学进展,2019;23(8):3284-3290。doi: 10.26355 / eurrev_201904_17690。PMID: 31081081。引用本文:马丽丽,谢晓文,马丽,庞建林,熊晓明,郑海华,沈晓玲,文志刚,王海燕。下调长链非编码RNA TRPM2-AS通过激活p53- p66shc通路抑制非小细胞肺癌细胞顺铂耐药。中华医学杂志,2017;21(11):2626-2634。PMID: 28678322。以下出版物因在大量文章中显示反复出现的结构模式和视觉内容(如Kaplan-Meier图、相关图等)而受到质疑:Li XF, Aierken AL, Shen L. IPO5通过激活MMP7促进食管癌的恶性进展。中华医学杂志,2020,24(8):446 -4254。doi: 10.26355 / eurrev_202004_21004。PMID: 32373960。高伟,杨刚,王军,何建明,王鹏。CSN6下调TIM
{"title":"Expression of Concern.","authors":"N Authors Listed","doi":"10.26355/eurrev_202506_37270","DOIUrl":"10.26355/eurrev_202506_37270","url":null,"abstract":"&lt;p&gt;&lt;p&gt;The Publisher, in agreement with the Editor-in-Chief, is issuing this Expression of Concern to inform readers that a formal investigation is currently underway regarding a set of published articles. Despite multiple attempts to contact the corresponding authors, we have not received any response to date. Further editorial actions, such as retraction or correction, will be taken as appropriate in due course. \u0000\u0000The articles under investigation fall into the following categories. \u0000\u0000These studies report extended follow-up periods, yet were published prior to the actual conclusion of the declared follow-up. This discrepancy raises serious concerns about the validity of the timeline and outcome reporting: \u0000Liao Y, Cheng S, Xiang J, Luo C. lncRNA CCHE1 increased proliferation, metastasis and invasion of non-small lung cancer cells and predicted poor survival in non-small lung cancer patients. Eur Rev Med Pharmacol Sci. 2018 Mar;22(6):1686-1692. doi: 10.26355/eurrev_201803_14581. PMID: 29630113. \u0000Yao N, Sun JQ, Yu L, Ma L, Guo BQ. LINC00968 accelerates the progression of epithelial ovarian cancer via mediating the cell cycle progression. Eur Rev Med Pharmacol Sci. 2019 Jun;23(11):4642-4649. doi: 10.26355/eurrev_201906_18043. PMID: 31210289. \u0000Hao XZ, Yang K. LncRNA MAGI2-AS3 suppresses the proliferation and invasion of non-small cell lung carcinoma through miRNA-23a-3p/PTEN axis. Eur Rev Med Pharmacol Sci. 2019 Sep;23(17):7399-7407. doi: 10.26355/eurrev_201909_18848. PMID: 31539127. \u0000Jiang J, Wu RH, Zhou HL, Li ZM, Kou D, Deng Z, Dong M, Chen LH. TGIF2 promotes cervical cancer metastasis by negatively regulating FCMR. Eur Rev Med Pharmacol Sci. 2020 Jun;24(11):5953-5962. doi: 10.26355/eurrev_202006_21488. PMID: 32572908. \u0000\u0000These articles have been questioned as they appear to reuse identical or similar graphical elements and images from a shared library across multiple unrelated studies: \u0000Xu CF, Liu P, Tan J, Hu DF. Long noncoding RNA LINC00052 suppressed the proliferation, migration and invasion of glioma cells by upregulating KLF6. Eur Rev Med Pharmacol Sci. 2019 Jun;23(11):4822-4827. doi: 10.26355/eurrev_201906_18068. PMID: 31210314. \u0000Zheng FX, Wang XQ, Zheng WX, Zhao J. Long noncoding RNA HOXA-AS2 promotes cell migration and invasion via upregulating IGF-2 in non-small cell lung cancer as an oncogene. Eur Rev Med Pharmacol Sci. 2019 Jun;23(11):4793-4799. doi: 10.26355/eurrev_201906_18064. PMID: 31210310.\u0000Liao J, Xie N. Long noncoding RNA DSCAM-AS1 functions as an oncogene in non-small cell lung cancer by targeting BCL11A. Eur Rev Med Pharmacol Sci. 2019 Feb;23(3):1087-1092. doi: 10.26355/eurrev_201902_16998. PMID: 30779076. \u0000Lu J, Xu FQ, Guo JJ, Lin PL, Meng Z, Hu LG, Li J, Li D, Lu XH, An Y. Long noncoding RNA GAS5 attenuates cardiac fibroblast proliferation in atrial fibrillation via repressing ALK5. Eur Rev Med Pharmacol Sci. 2019 Sep;23(17):7605-7610. doi: 10.26355/eurrev_201909_18883. PMID: 31539152. \u0000Shi JQ, Wang B, Cao XQ, Wang YX, Cheng ","PeriodicalId":12152,"journal":{"name":"European review for medical and pharmacological sciences","volume":"29 6","pages":"287-288"},"PeriodicalIF":3.3,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144559622","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Exploring nutraceutical solutions for prediabetes: a narrative review on the effects of banaba and chromium picolinate. 探索糖尿病前期的营养解决方案:对香蕉和吡啶甲酸铬的影响的叙述综述。
IF 3.3 4区 医学 Q1 Medicine Pub Date : 2025-06-01 DOI: 10.26355/eurrev_202506_37275
G Derosa, P Maffioli, A D'Angelo, V Foscaldi, R Piazza, M Mangrella, F Fogacci, A F G Cicero

Prediabetes is an intermediary metabolic state marked by impaired glucose control, often preceding the development of type 2 diabetes (T2D). Early detection of prediabetes and intervention are critical to prevent the progression to T2D and its associated complications. This review examines the effects of nutraceuticals on regulating metabolism, with a focus on glucose control, specifically chromium picolinate (CrP) and banaba leaf extract. CrP has been extensively studied, and its role in regulating metabolism has been officially recognized. Preclinical research demonstrates its ability to improve glucose control by enhancing insulin sensitivity. These effects explain the reductions in fasting plasma glucose, elevated hemoglobin A1c, and insulin levels observed in clinical studies, particularly in patients with T2D. Banaba (Lagerstroemia speciosa) leaf extract, rich in corosolic acid and ellagitannins, has also shown promising results in improving glycemic control. As observed in preclinical studies, both banaba extract and corosolic acid exert insulin-sensitizing, glucose-lowering, and lipid-lowering properties. Clinical trials have confirmed these effects in individuals with T2D and prediabetes. Based on this evidence, combining CrP and banaba leaf extract may offer synergistic benefits in managing dysglycemia and delaying the onset of T2D in individuals with prediabetes. Only one study has evaluated the effects of the CrP and banaba extract combination, showing positive outcomes in individuals with prediabetes. Further research is needed to corroborate these preliminary findings. In conclusion, nutraceuticals like CrP and banaba leaf extract hold promise as complementary therapies to be used alongside lifestyle modifications for individuals with prediabetes.

Graphical abstract: https://www.europeanreview.org/wp/wp-content/uploads/Graphical-Abstract-1-1-scaled.jpg.

前驱糖尿病是一种中间代谢状态,以葡萄糖控制受损为标志,通常在2型糖尿病(T2D)发展之前。糖尿病前期的早期发现和干预对于预防t2dm及其相关并发症的进展至关重要。本文综述了营养保健品在调节代谢方面的作用,重点是葡萄糖控制,特别是吡啶甲酸铬(CrP)和香蕉叶提取物。CrP已被广泛研究,其在调节代谢中的作用已被正式认可。临床前研究表明,它能够通过增强胰岛素敏感性来改善血糖控制。这些影响解释了临床研究中观察到的空腹血糖降低、糖化血红蛋白升高和胰岛素水平降低,特别是在糖尿病患者中。香蕉(Lagerstroemia speciosa)叶提取物富含花椰树酸和鞣花单宁,在改善血糖控制方面也有很好的效果。在临床前研究中观察到,香蕉提取物和科罗索酸都具有胰岛素增敏、降血糖和降脂的特性。临床试验证实了这些作用在T2D和前驱糖尿病患者身上。基于这一证据,将CrP和香蕉叶提取物联合使用可能在糖尿病前期患者控制血糖异常和延迟T2D发作方面提供协同效益。只有一项研究评估了CrP和香蕉提取物组合的效果,显示出对糖尿病前期患者的积极效果。需要进一步的研究来证实这些初步发现。总之,像c蛋白和香蕉叶提取物这样的营养保健品有望作为补充疗法,与改变生活方式一起用于糖尿病前期患者。图形摘要:https://www.europeanreview.org/wp/wp-content/uploads/Graphical-Abstract-1-1-scaled.jpg。
{"title":"Exploring nutraceutical solutions for prediabetes: a narrative review on the effects of banaba and chromium picolinate.","authors":"G Derosa, P Maffioli, A D'Angelo, V Foscaldi, R Piazza, M Mangrella, F Fogacci, A F G Cicero","doi":"10.26355/eurrev_202506_37275","DOIUrl":"https://doi.org/10.26355/eurrev_202506_37275","url":null,"abstract":"<p><p>Prediabetes is an intermediary metabolic state marked by impaired glucose control, often preceding the development of type 2 diabetes (T2D). Early detection of prediabetes and intervention are critical to prevent the progression to T2D and its associated complications. This review examines the effects of nutraceuticals on regulating metabolism, with a focus on glucose control, specifically chromium picolinate (CrP) and banaba leaf extract. CrP has been extensively studied, and its role in regulating metabolism has been officially recognized. Preclinical research demonstrates its ability to improve glucose control by enhancing insulin sensitivity. These effects explain the reductions in fasting plasma glucose, elevated hemoglobin A1c, and insulin levels observed in clinical studies, particularly in patients with T2D. Banaba (Lagerstroemia speciosa) leaf extract, rich in corosolic acid and ellagitannins, has also shown promising results in improving glycemic control. As observed in preclinical studies, both banaba extract and corosolic acid exert insulin-sensitizing, glucose-lowering, and lipid-lowering properties. Clinical trials have confirmed these effects in individuals with T2D and prediabetes. Based on this evidence, combining CrP and banaba leaf extract may offer synergistic benefits in managing dysglycemia and delaying the onset of T2D in individuals with prediabetes. Only one study has evaluated the effects of the CrP and banaba extract combination, showing positive outcomes in individuals with prediabetes. Further research is needed to corroborate these preliminary findings. In conclusion, nutraceuticals like CrP and banaba leaf extract hold promise as complementary therapies to be used alongside lifestyle modifications for individuals with prediabetes.</p><p><strong>Graphical abstract: </strong>https://www.europeanreview.org/wp/wp-content/uploads/Graphical-Abstract-1-1-scaled.jpg.</p>","PeriodicalId":12152,"journal":{"name":"European review for medical and pharmacological sciences","volume":"29 6","pages":"324-338"},"PeriodicalIF":3.3,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144559621","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Prognostic role of miR-190, miR-221, and miR-381 in breast cancer: a systematic review and meta-analysis. miR-190、miR-221和miR-381在乳腺癌中的预后作用:一项系统综述和荟萃分析
IF 3.3 4区 医学 Q1 Medicine Pub Date : 2025-06-01 DOI: 10.26355/eurrev_202506_37272
S Matsas, A Ruiz Simões, P Nazareth Aguiar, Y Abdou, H Krontiras, A Del Giglio

OBJECTIVE: Breast cancer is the most frequently diagnosed malignancy in women and a leading cause of cancer-related mortality. Conventional prognostic tools may not fully capture disease outcomes. MicroRNA (miR) expression has emerged as a potential prognostic factor, though findings remain inconsistent. This systematic review and meta-analysis assess the prognostic role of miR-190, miR-221, and miR-381 in predicting overall survival (OS) among breast cancer patients. MATERIALS AND METHODS: A comprehensive literature search in PubMed, Embase, and Scopus identified relevant studies. Pooled hazard ratios (HRs) and 95% confidence intervals (CIs) were calculated to assess the relationship between miR expression and OS. Subgroup analyses were conducted to explore potential sources of heterogeneity. RESULTS: Four studies on miR-221, four on miR-190, and three on miR-381 met inclusion criteria. High miR-190 expression was significantly associated with improved OS (HR: 0.63; 95% CI: 0.47-0.84), as was miR-381 (HR: 0.64; 95% CI: 0.52-0.79). No significant association was found between miR-221 expression and OS (HR: 1.12; 95% CI: 0.86-1.46). Subgroup analysis reinforced these findings, and Newcastle-Ottawa scale assessment indicated low publication bias in 10 out of 11. CONCLUSIONS: Elevated miR-190 and miR-381 levels are associated with improved OS in breast cancer, whereas the prognostic role of miR-221 remains unclear. These findings underscore the potential of miR-190 and miR-381 as prognostic biomarkers.

Graphical abstract: https://www.europeanreview.org/wp/wp-content/uploads/Graphical-Abstract-18-scaled.jpg.

目的:乳腺癌是女性中最常见的恶性肿瘤,也是癌症相关死亡的主要原因。传统的预后工具可能无法完全捕捉疾病的结果。MicroRNA (miR)表达已成为潜在的预后因素,尽管研究结果仍不一致。本系统综述和荟萃分析评估了miR-190、miR-221和miR-381在预测乳腺癌患者总生存期(OS)中的预后作用。材料和方法:在PubMed, Embase和Scopus中进行综合文献检索,确定相关研究。计算合并风险比(hr)和95%置信区间(ci)来评估miR表达与OS之间的关系。进行亚组分析以探索异质性的潜在来源。结果:4项关于miR-221的研究,4项关于miR-190的研究,3项关于miR-381的研究符合纳入标准。miR-190高表达与OS改善显著相关(HR: 0.63;95% CI: 0.47-0.84), miR-381也是如此(HR: 0.64;95% ci: 0.52-0.79)。miR-221表达与OS无显著相关性(HR: 1.12;95% ci: 0.86-1.46)。亚组分析强化了这些发现,纽卡斯尔-渥太华量表评估显示,11篇文章中有10篇的发表偏倚较低。结论:miR-190和miR-381水平升高与乳腺癌OS改善相关,而miR-221在预后中的作用尚不清楚。这些发现强调了miR-190和miR-381作为预后生物标志物的潜力。图形摘要:https://www.europeanreview.org/wp/wp-content/uploads/Graphical-Abstract-18-scaled.jpg。
{"title":"Prognostic role of miR-190, miR-221, and miR-381 in breast cancer: a systematic review and meta-analysis.","authors":"S Matsas, A Ruiz Simões, P Nazareth Aguiar, Y Abdou, H Krontiras, A Del Giglio","doi":"10.26355/eurrev_202506_37272","DOIUrl":"10.26355/eurrev_202506_37272","url":null,"abstract":"<p><p>OBJECTIVE: Breast cancer is the most frequently diagnosed malignancy in women and a leading cause of cancer-related mortality. Conventional prognostic tools may not fully capture disease outcomes. MicroRNA (miR) expression has emerged as a potential prognostic factor, though findings remain inconsistent. This systematic review and meta-analysis assess the prognostic role of miR-190, miR-221, and miR-381 in predicting overall survival (OS) among breast cancer patients. MATERIALS AND METHODS: A comprehensive literature search in PubMed, Embase, and Scopus identified relevant studies. Pooled hazard ratios (HRs) and 95% confidence intervals (CIs) were calculated to assess the relationship between miR expression and OS. Subgroup analyses were conducted to explore potential sources of heterogeneity. RESULTS: Four studies on miR-221, four on miR-190, and three on miR-381 met inclusion criteria. High miR-190 expression was significantly associated with improved OS (HR: 0.63; 95% CI: 0.47-0.84), as was miR-381 (HR: 0.64; 95% CI: 0.52-0.79). No significant association was found between miR-221 expression and OS (HR: 1.12; 95% CI: 0.86-1.46). Subgroup analysis reinforced these findings, and Newcastle-Ottawa scale assessment indicated low publication bias in 10 out of 11. CONCLUSIONS: Elevated miR-190 and miR-381 levels are associated with improved OS in breast cancer, whereas the prognostic role of miR-221 remains unclear. These findings underscore the potential of miR-190 and miR-381 as prognostic biomarkers.</p><p><strong>Graphical abstract: </strong>https://www.europeanreview.org/wp/wp-content/uploads/Graphical-Abstract-18-scaled.jpg.</p>","PeriodicalId":12152,"journal":{"name":"European review for medical and pharmacological sciences","volume":"29 6","pages":"301-312"},"PeriodicalIF":3.3,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144559624","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
European review for medical and pharmacological sciences
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1